SCHEMBL1498705

SCHEMBL1498705

CCc1cc(O)c(OC)cc1F

nearest known ligand 0.61

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HMGCR P04035 2/20 0.47
TAAR1 Q96RJ0 3/20 0.43
JAK2 O60674 1/20 0.41
JAK1 P23458 1/20 0.41
TYK2 P29597 1/20 0.41
KDR P35968 1/20 0.41
JAK3 P52333 1/20 0.41
AURKB Q96GD4 1/20 0.41
MTNR1A P48039 1/20 0.41
MTNR1B P49286 1/20 0.41
TSHR P16473 2/20 0.41
MAPK1 P28482 1/20 0.41
HSD17B2 P37059 1/20 0.40
BACE1 P56817 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
NFKB1 P19838 1/20 0.40
LMNA P02545 1/20 0.40
GLA P06280 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1498704 0.92 HMGCR (0.52) HMGCRTAAR1MTNR1AMTNR1BTSHR
SCHEMBL13618030 0.84 TAAR1 (0.53) HMGCRTAAR1MTNR1AMTNR1BCYP3A4
SCHEMBL11919300 0.82 TAAR1 (0.47) HMGCRTAAR1MTNR1AMTNR1BMAPK1
SCHEMBL1044562 0.79 MAOB (0.48) HMGCRTAAR1TSHRMAPK1CYP1A2
SCHEMBL7723931 0.79 ALOX15 (0.45) MAPK1BACE1LMNA
SCHEMBL26664827 0.78 HMGCR (0.48) HMGCRTAAR1TSHRMAPK1HSD17B2
SCHEMBL20399474 0.78 HMGCR (0.48) HMGCRTAAR1TSHRMAPK1HSD17B2
SCHEMBL28962328 0.78 HSD17B2 (0.45) HMGCRTAAR1TSHRHSD17B2CYP1A2
SCHEMBL15706606 0.78 TAAR1 (0.47) TAAR1MTNR1AMTNR1BGLA
SCHEMBL9955637 0.78 TAAR1 (0.41) HMGCRTAAR1JAK2JAK1TYK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2473480-B1 NOVEL ANTIBACTERIAL HYDROXYPHENYL COMPOUND FAB PHARMA SAS (FR) 2016-06-01 EP disclosed
US-9272985-B2 Antibacterial hydroxyphenyl compound FAB PHARMA S.A.S. (FR) 2016-03-01 US disclosed
US-20120232155-A1 NOVEL ANTIBACTERIAL HYDROXYPHENYL COMPOUND FAB PHARMA S.A.S. (FR) 2012-09-13 US disclosed
EP-2473480-A1 NOVEL ANTIBACTERIAL HYDROXYPHENYL COMPOUND FAB Pharma SAS (FR) 2012-07-11 EP disclosed
WO-2011026529-A1 NOVEL ANTIBACTERIAL HYDROXYPHENYL COMPOUND FAB PHARMA SAS (FR) 2011-03-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120232155-A1 NOVEL ANTIBACTERIAL HYDROXYPHENYL COMPOUND MRPL21, VIP, DHPS HMGCR 288/4885TAAR1 4823/4885JAK2 3790/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.